<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083521</url>
  </required_header>
  <id_info>
    <org_study_id>DE111Reg</org_study_id>
    <nct_id>NCT04083521</nct_id>
  </id_info>
  <brief_title>Effect of Bacillus Subtilis DE111® on Daily Bowel Movements</brief_title>
  <official_title>The Effect of Bacillus Subtilis DE111® on the Daily Bowel Movement Profile for People With Occasional Gastrointestinal Irregularity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deerland Enzymes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kennesaw State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deerland Enzymes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Bacillus subtilis DE111® probiotic&#xD;
      for regulation of bowel movements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the efficacy of the probiotic B. subtilis DE111®&#xD;
      for regulation of bowel movements. A single capsule containing 1 x 10^9 CFU B. subtilis is to&#xD;
      be consumed once a day per participant. 50 adults (18-65 years of age at the time of&#xD;
      participation) suffering from occasional constipation and/or diarrhea will be enrolled.&#xD;
      Participants will be double-blindly and randomly assigned to either the probiotic (Bacillus&#xD;
      subtilis) or the placebo (maltodextrin) group. Efficacy will be assessed with&#xD;
      participant-reported bowel movement (BM) records. As a secondary outcome, the study will&#xD;
      provide further insight into the tolerance of the supplement. Tolerance will be assessed&#xD;
      using a digestive health questionnaire and blood samples to analyze pertinent metabolic&#xD;
      biomarkers. Participants will be asked to complete a daily dietary intake record as well.&#xD;
      Prior to capsule consumption, participants will complete a two-week pre-testing phase in&#xD;
      order to provide a more inclusive diagnostic baseline. This phase will consist of daily BM&#xD;
      and dietary intake record keeping.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel movement regularity</measure>
    <time_frame>105-day study period (consisting of 90-days treatment plus 15-day follow up)</time_frame>
    <description>Increasing regularity of bowel movements in subjects with occasional diarrhea or constipation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance</measure>
    <time_frame>105-day study period (consisting of 90-days treatment plus 15-day follow up)</time_frame>
    <description>To determine if the supplement is tolerable among subjects without causing adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Bowel Movement Regulation</condition>
  <condition>Occasional Constipation</condition>
  <condition>Occasional Diarrhea</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects received a once daily dose of maltodextrin for 90-days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bacillus subtilis DE111®</intervention_name>
    <description>Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants suffering from occasional constipation and/or diarrhea will be eligible&#xD;
             for participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood CRP levels for each participant will be monitored at days 0, 60 and 105 of this&#xD;
             study. Participants with CRP levels greater than 5mg/l on day 0 of the study will be&#xD;
             excluded from further participation as this level is indicative of underlying&#xD;
             inflammatory bowel disease. Participants excluded under such conditions will be&#xD;
             instructed to seek further treatment with their health care provider.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kennesaw State University</name>
      <address>
        <city>Kennesaw</city>
        <state>Georgia</state>
        <zip>30144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bowel movement regulation</keyword>
  <keyword>Occasional constipation</keyword>
  <keyword>Occasional diarrhea</keyword>
  <keyword>Gastrointestinal health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

